November 22, 2018
Oasmia’s Apalea approved in Europe for ovarian cancer
After the Oasmia Pharmaceutical’s pivotal study OAS 07OVA conducted on ovarian cancer patients with disease relapse, showed that the risks…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
November 22, 2018
GSK, Kyowa Hakko Kirin mutual work on potential oral treatment for CKD related anaemia
GSK and Kyowa Hakko Kirin will together commercialize in Japan the treatment of chronic kidney disease related anaemina, which GKS…
November 21, 2018
Sandoz, Pear Therapeutics launch reSET for patients with Substance Use Disorder
Novartis’s division Sandoz, and Pear Therapeutics, have launched reSET for patients with Substance Use Disorder (SUD), which is th efirst…
November 21, 2018
Indivior trusts its portfolio, aware of challenges for Suboxone
Indivior PLC said Wednesday said in a statement it is dissapointed by the US District Court for the District of…
November 20, 2018
Swedish Oasmia Pharmaceutical’s nanotechnology platform XR17 patented in USA
Swedish Oasmia Pharmaceutical said on Tuesday that it got a patent for its unique nanotech method to produce novel pharmaceutical formulations, from the United States Patent and Trademark Office (USPTO).
November 20, 2018
Denali Therapeutics’ RIPK1 inhibitor molecule shows well in clinical test
Denali Therapeutics, a neurodegenerative diseases specialist, on Tuesday brought to public positive results from its Phase 1 healthy volunteer study of DNL747, a brain penetrant small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1),
November 20, 2018
SkinBioTherapeutics kicks off final phase of SkinBiotix study
SkinBioTherapeutics has begun the final phases of its human study of SkinBiotix, to ensure that the original technology retains the same…
November 19, 2018
Immunocore, Genentech in skin cancer T-cell redirection therapy co-development
A T Cell Receptor (TCR) biotechnology specialist Immunocore Limited, has entered into a new partnership with Genentech, a member of…
November 14, 2018
Basilea presents anticancer drug candidate on a symposium in Ireland
Basilea Pharmaceutica will presenting its new preclinical data on its clinical stage anticancer drug candidate BAL101553 at the 30 EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
November 8, 2018
FDA prioritizes Dupinex for review
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the @Regeneron Pharmaceuticals and Sanofi made supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.